Key Takeaways Avanos Medical posted robust Q2 growth in SNS and solid RFA sales in Pain Management and Recovery.AVNS' transformation plan includes divestitures and acquisitions.Tariffs and FX volatility remain key risks, with $8M in Q2 costs and potential revenue pressure in 2025.Avanos Medical, Inc. (AVNS) is well-poised for growth in the coming quarters, courtesy of its impressive product line. The optimism, led by a decent fiscal second-quarter 2025 performance and continued robust product performance, i ...